Learn More
Apexbio Technology LLC PCI-32765 (Ibrutinib) 936563-96-1 10mM (in 1mL DMSO)

Supplier: Apexbio Technology LLC A30015.1
PCI-32765 (Ibrutinib) is a small-molecule inhibitor targeting Bruton s tyrosine kinase (BTK) a cytoplasmic kinase integral to B-cell receptor (BCR) signaling By covalently binding to BTK active sites PCI-32765 disrupts downstream signaling cascades essential for B-cell maturation and activation Dysfunction or inhibition of BTK correlates with impaired B-cell development and reduction in autoantibody production PCI-32765 is commonly utilized in biomedical research to explore BTK-dependent signaling pathways elucidate molecular mechanisms underlying B-cell mediated disorders and examine therapeutic potential in B-cell malignancies and autoimmune models
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.